Building NGS quality management for the move from research use toward regulated or clinical testing is the transition labs most consistently underestimate, because they misjudge what the barrier actually is. The instinct is to assume the hard part is technical: better instruments, tighter chemistry, more sensitive assays. In practice the research lab and the clinical lab down the hall often run the same instruments and similar chemistries. What separates them is the quality system, the validation records, the accreditation, the documented training, the proficiency testing, and the contamination controls, none of which is visible in the data and all of which takes time to build. That build is frequently a multi-year effort, and treating it as a technical upgrade rather than a quality-system construction is the most common reason the timeline slips.
This overview maps what changes on that journey, and it uses regulatory terms precisely because imprecision here is expensive. It distinguishes research use from regulated use, sets out what assay validation and accreditation actually require, and covers the proficiency testing, training records, and contamination control that a quality system rests on. It stays on the operations of laboratory quality and compliance; it is a map of the territory, not legal advice, and the specific requirements that apply to any given lab depend on its jurisdiction and the tests it runs.
Key Takeaways
|
Research Use vs. Regulated Use
The distinction that governs everything else is between research use and regulated clinical use, because the two operate under fundamentally different obligations. A research lab generates data to answer scientific questions, and while good research demands rigor, it is not bound by the regulatory quality framework that governs testing used to inform patient care. A clinical lab produces results that guide medical decisions, and it operates under mandatory oversight, documented validation, defined personnel qualifications, and continuous quality monitoring. The difference is not how good the science is. It is whether a formal, auditable quality system stands behind every result.
Between the two sits a category worth naming: research results that later need to support regulated work. Data generated in a research setting generally cannot simply be repurposed for clinical use, because it was not produced under the required quality system, which is why a lab contemplating an eventual move toward clinical testing benefits enormously from building quality-system habits early. The instrument qualification that underpins this, and the difference between research-use and regulated-use expectations for it, is covered in Installation and Instrument Qualification: IQ, OQ, and PQ for Sequencers.
Dimension | Research Use | Regulated / Clinical Use |
Purpose | Answer scientific questions | Inform patient care decisions |
Oversight | Institutional and funder norms | Mandatory regulatory framework |
Assay validation | Fit for the study | Formally validated and documented |
Personnel | Qualified for the research | Defined regulatory qualifications |
Documentation | Lab notebook standard | Auditable quality-system records |
Quality monitoring | As the science requires | Continuous, with proficiency testing |
Table 1. What changes between research use and regulated clinical use. The instruments may be identical; the quality system around them is not.
Assay Validation Requirements
Validation is where the documentation gap is widest, because clinical assay validation is a categorically larger exercise than the informal validation research work relies on. A clinical NGS assay must be formally validated and documented against defined performance characteristics before it can be used to report patient results: accuracy, precision, analytical sensitivity, analytical specificity, reportable range, and reference range, each established through a designed validation study with predefined acceptance criteria and a retained record. This is not a matter of confirming the assay works; it is a matter of proving, on the record, exactly how well it works and within what limits.
For sequencing specifically, validation also has to address the characteristics unique to the technology, including the types of variant the assay can and cannot reliably detect, the limits of detection for those variant types, the depth of coverage required, and how the bioinformatics pipeline is versioned and controlled, since a change to the analysis software can change the result as surely as a change to the wet-lab method. The full validation process, from development through clinical use, is developed in Validating an NGS Assay for Clinical Use. Validation builds directly on the performance qualification established at installation, so a lab that documented qualification well has a head start it should not squander.
Lab Quality Management Certificate
The Lab Quality Management certificate is more than training—it’s a professional advantage.
Gain critical skills and IACET-approved CEUs that make a measurable difference.
Accreditation Pathways
The accreditation landscape is where imprecise language does the most damage, because the major frameworks are different kinds of thing and are not interchangeable. Confusing them leads to real planning errors, so it is worth stating each one’s nature exactly.
Framework | What It Is | What That Means |
CLIA | US federal law | Mandatory for any US laboratory testing human samples for clinical purposes; administered by the Centers for Medicare and Medicaid Services; sets minimum standards |
CAP | US accreditation program | Voluntary accreditation from the College of American Pathologists that holds federal deemed status, so CAP accreditation can satisfy the equivalent CLIA requirements; peer-based inspection |
ISO 15189 | International standard | A voluntary international standard for quality and competence in medical laboratories, not legally binding unless adopted into a jurisdiction’s framework; accredits at the level of specific tests |
IVDR | EU regulation | The European Union regulation governing in vitro diagnostic medical devices, in force with a phased, ongoing transition; relevant to labs operating in or placing tests on the EU market |
Table 2. The four frameworks a sequencing lab encounters, by what each one actually is. They are not alternatives to one another; a single lab may be subject to several at once.
These Four Are Not Alternatives to Each Other A US clinical lab is subject to CLIA by law and may additionally pursue CAP accreditation, which can satisfy its CLIA obligations through deemed status, and may also seek ISO 15189 accreditation to demonstrate quality to an international standard. A lab placing diagnostic tests on the EU market engages with IVDR regardless of its US status. These frameworks stack and overlap rather than competing, and choosing between them is the wrong mental model. The right question is which of them apply to your jurisdiction, your market, and the tests you run, and the answer is frequently more than one. |
Because the specific requirements, inspection processes, and personnel standards differ across these frameworks, the detailed accreditation pathways are treated separately in CLIA, CAP, and ISO 15189: Accreditation Requirements for Sequencing Labs.
Proficiency Testing
Accreditation is not a one-time achievement, and proficiency testing is the clearest example of why. A regulated laboratory must participate in ongoing external quality assessment, periodically testing blind samples of known composition provided by an external scheme and comparing its results against the expected answer and against peer laboratories. It is how a lab demonstrates, continuously and to an outside party, that its results remain accurate over time rather than merely having been accurate on the day it was accredited.
Interested in lab leadership?
For next-generation sequencing, proficiency testing carries particular complexity, because a scheme has to probe the assay’s ability to detect the specific variant types it claims to report, across the range of conditions it operates in, which is a harder target than a single analyte measurement. Where a formal external scheme does not exist for a given specialized assay, the lab is generally expected to establish an alternative assessment approach. The detailed treatment of external quality assessment for sequencing is in Proficiency Testing and External Quality Assessment for NGS.
Training and Competency Records
In a regulated setting, staff competence is not assumed from a qualification or a job title; it is assessed, documented, and reassessed on a defined schedule, and the records are part of what an inspection examines. Every person performing a step that affects a reportable result must have a documented record showing they were trained on the current procedure, assessed as competent to perform it, and periodically reassessed to confirm that competence has been maintained. A capable team whose competence is undocumented does not meet the standard, because in a regulated environment an activity that is not documented is treated as not having happened.
This is often a cultural shift as much as a procedural one for a lab coming from a research background, where competence is real but informally held. Building the habit of documenting training and competency from the start is far easier than reconstructing it later, and it connects to the broader operational discipline of running a sequencing lab at scale covered in Running NGS at Scale: Throughput, Scheduling, and Automation. The practical mechanics of building a training and competency program are developed in Training Lab Staff on NGS Platforms: A Practical Playbook.
Contamination Control
Contamination control matters in any sequencing lab, but in a regulated setting it becomes a documented, auditable program rather than a matter of good habits. Because sequencing workflows amplify nucleic acid, cross-contamination between samples or from previously amplified product can produce false results, and a clinical lab must both prevent this through physical and procedural controls and document that the controls are in place and working. That means workflow and workspace separation between pre-amplification and post-amplification areas, unidirectional workflow, defined cleaning procedures, and monitoring through negative controls that would reveal contamination if it occurred.
The physical separation this requires is a facility consideration that is far cheaper to design in from the start than to retrofit, which is one reason it connects back to the earliest planning of the lab, including the readiness assessment in Is Your Lab Ready for NGS? A Readiness Assessment. The detailed program, including monitoring and response, is covered in Contamination Control in the Sequencing Lab. Across every one of these areas, the lesson is the same one the timeline teaches: the quality system is the real work of going clinical, it takes longer than the instrument purchase that gets all the attention, and the labs that start building it early are the ones whose two-year journey does not become a four-year one. The full operational picture that this quality layer sits on top of is in Next-Generation Sequencing in the Lab: A Manager’s Guide to Building, Budgeting, and Scaling NGS Capacity.
This article was produced under Lab Manager's AI Editorial Guidelines.
